Semaglutide's medication class and what it means for weight management

Step 1: understanding what a GLP-1 receptor agonist actually does

GLP-1 (glucagon-like peptide-1) is a hormone your gut secretes naturally, mostly in response to food. Its job is to tell the pancreas to release insulin, slow the movement of food out of the stomach, and send satiety signals to the brain. Semaglutide is a synthetic molecule engineered to bind to the same receptor that GLP-1 uses, but it stays active in the body far longer than the natural hormone does. That extended action is what makes a once-weekly injection or daily tablet practical.

Because the GLP-1 receptor is found in multiple tissues (the gut, the pancreas, and appetite-regulating centres in the brain) semaglutide's effects are broader than simply feeling a little less hungry at mealtimes. People taking it often report that food feels less urgent, that portion sizes that once felt too small now feel comfortable, and that cravings for high-calorie foods quiet down noticeably. These aren't willpower changes; they reflect the medicine doing its job at receptor level.

Semaglutide is not the only GLP-1 receptor agonist available. Liraglutide (daily injection, Saxenda) works through the same receptor, as does tirzepatide, though tirzepatide adds a second target, the GIP receptor, making it a dual agonist in a different sub-class. You can read more about how semaglutide's drug class compares to other GLP-1 medicines if that distinction matters to your decision.

Step 2: the brand names, licensed uses, and why they matter

The active ingredient is semaglutide in each case, but the brand name signals the licensed indication, and that distinction is legally and clinically significant in the UK. Ozempic (weekly injection, 0.5mg–2mg) is licensed for type 2 diabetes. Wegovy (weekly injection, 0.25mg escalating to 2.4mg, with a higher 7.2mg dose now approved by the MHRA) is licensed for weight management. Wegovy tablets, approved by the MHRA on 11 June 2026 as the UK's first oral GLP-1 weight-loss medicine, escalate from 1.5mg to a 25mg maintenance dose once daily.

Prescribing Ozempic for weight loss (sometimes called off-label use) is outside its UK licence. A prescriber can do so in specific circumstances, but it is not the same as prescribing the medicine that was studied, approved, and licensed for that purpose. If weight management is your goal, Wegovy is the relevant semaglutide product; you can find a full overview on the Wegovy medication guide. For clarity on the different names semaglutide travels under, the semaglutide brand names page covers the full picture.

One practical habit worth building: before you hand over any details or payment to an online provider, spend sixty seconds checking that their pharmacy appears on the GPhC register. Every legitimate UK online pharmacy must be listed there. If it isn't, stop.

Step 3: what the clinical evidence shows, and what it doesn't promise

The trial evidence for semaglutide at its weight-management doses is solid. In the STEP 1 trial, published in the New England Journal of Medicine, adults taking 2.4mg semaglutide alongside lifestyle changes lost around 15% of their body weight on average over 68 weeks, a meaningful reduction by any clinical measure. The newer 7.2mg dose has reported around 20.7% average loss over 72 weeks in trial data, narrowing the gap with higher-dose tirzepatide considerably. NICE's appraisal of semaglutide for weight management (NICE TA875) concluded it was clinically effective within a specialist weight management service for eligible adults.

Those averages, though, represent distributions. Some people lose more, some less; a meaningful minority don't respond sufficiently, and NICE guidance notes that treatment should be reconsidered if less than 5% weight loss is achieved after six months at the maintenance dose. The medication works with your biology, not against it, which means factors like starting weight, existing conditions, and how closely lifestyle changes are maintained all influence outcomes. No number from a trial translates automatically into a personal guarantee.

Cost is a real consideration for most people. The Wegovy pricing guide covers what private treatment typically costs in the UK and what a legitimate price includes. That context is worth reading before comparing figures from different providers.

Step 4: what being in the GLP-1 class means for side effects and safety

Because all GLP-1 receptor agonists share the same mechanism, they share a broadly similar side-effect profile. Gastrointestinal effects (nausea, loose stools, constipation, indigestion) are the most commonly reported. They tend to be most noticeable in the early weeks and after dose increases, then settle for most people. Starting at a low dose and titrating slowly exists precisely to give the body time to adapt; the schedule isn't arbitrary.

Rarer but serious effects are worth knowing about. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as an infrequent but potentially serious risk across GLP-1 medicines: seek urgent medical attention for severe stomach pain that spreads to the back, especially alongside vomiting. Gallbladder problems, including gallstones, have also been reported. These are not reasons to avoid the medicine if it's clinically right for you, they are reasons to be informed and to have access to proper aftercare, not just a delivery address.

Interactions with other medicines are worth discussing openly at consultation. One specific issue for tirzepatide (not semaglutide specifically, but relevant context for the drug class) involves oral contraceptives and absorption. For semaglutide, the evidence of reduced pill effectiveness is less clear, but your prescriber should have the full picture of what you take; if you want background on what the semaglutide class covers and which medicines belong to it, that page sets out the full picture. Our guide on semaglutide and ADHD medicines covers one common interaction question in detail. For anything medication-specific, the prescriber assessing your consultation is the right source, not a forum.